

Genetically Controlled Upregulation of Adenosine A₁ Receptor Expression Enhances the Survival of Primary Cortical Neurons

Tsvetan Serchov · Hasan-Cem Atas · Claus Normann · Dietrich van Calker · Knut Biber

Received: 5 July 2012 / Accepted: 2 August 2012 / Published online: 17 August 2012
© Springer Science+Business Media, LLC 2012

Abstract Adenosine has a key endogenous neuroprotective role in the brain, predominantly mediated by the adenosine A₁ receptor (A₁R). This has been mainly explored using pharmacological tools and/or receptor knockout mice strains. It has long been suggested that the neuroprotective effects of A₁R are increased following receptor upregulation, thus attenuating neuronal damage in pathological conditions. We have previously shown that the neuroprotective and neuromodulatory actions of the cytokines IL-6 and oncostatin M are mediated by induction of neuronal A₁R expression. In order to investigate the direct effects of A₁R upregulation in neurons, we have generated a tetracycline-regulated expression system with a bidirectional promoter, directing the simultaneous expression of the mouse A₁R and GFP/mCherry reporter genes. In a first step, we tested the efficacy of the system in transiently transfected human embryonic kidney 293 cells. In addition, we confirmed the functional integrity of the expressed A₁R by whole-cell patch clamp recordings. We demonstrated that A₁R-transfected primary neurons show enhanced survival against *N*-methyl-D-aspartate-induced excitotoxicity. Pretreatment with an A₁R-selective agonist additionally strongly decreased

neuronal cell death, while an A₁R antagonist completely abolished the neuroprotective effects of A₁R upregulation. The presented data provide for the first time direct evidence that the upregulation of A₁R enhances neuronal survival.

Keywords Adenosine A₁ receptor · Overexpression · Excitotoxicity · Neuroprotection · Tetracycline expression system · Transfection

Introduction

Glutamate-mediated excitotoxicity is a major area of interest because of its involvement in brain trauma, stroke and many neurodegenerative disorders. This process is mediated by excessive activation of glutamate receptors and has been associated with neuronal loss observed after epileptic seizures, spinal cord and head injury [1–3] and many neurodegenerative disorders, such as Parkinson's disease, Alzheimer's disease, Huntington's disease and multiple sclerosis [4].

Excitotoxicity causes a pronounced increase of adenosine levels in the affected brain tissue (see for review [5]). The extracellular adenosine acts as a major neuroprotective system in the brain, and its effects are predominantly mediated by adenosine A₁ receptor (A₁R). The A₁R suppresses neuronal activity by presynaptic inhibition of glutamate release [6] and postsynaptic hyperpolarization of the cell membrane, caused by increasing the conductance of K⁺ channels [7], inhibition of Ca²⁺ influx through voltage-dependent Ca²⁺ channels and stabilisation of the Mg²⁺ blockade of *N*-methyl-D-aspartate (NMDA) receptors [8].

The neuroprotective role of A₁R in the brain has been explored mainly by taking advantage of different pharmacological tools, like selective agonists such as *N*⁶-cyclopentyladenosine (CPA) and 2-chloroadenosine and antagonists such as 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) in

Electronic supplementary material The online version of this article (doi:10.1007/s12035-012-8321-6) contains supplementary material, which is available to authorized users.

T. Serchov · H.-C. Atas · C. Normann · D. van Calker · K. Biber (✉)
Department of Psychiatry and Psychotherapy,
University of Freiburg,
Hauptstrasse 5,
79104 Freiburg, Germany
e-mail: knut.biber@uniklinik-freiburg.de

K. Biber
Department of Neuroscience,
University Medical Center Groningen,
Ant. Deusinglaan 1,
9713 AV Groningen, The Netherlands

combination with several receptor knockout mice strains (see for review [9]). However, the A₁R agonists are not used for therapeutic purposes, mostly due to severe peripheral side effects, short half-life and/or receptor desensitization [10, 11]. It has been suggested that the induction of A₁R expression might efficiently enhance A₁R-mediated neuroprotection (see for review [5, 12, 13]). Indeed, we have recently reported that the upregulation of A₁R expression is a key mechanism that mediates the neuroprotective function of IL-6 and oncostatin M cytokines [14, 15].

Thus, in order to study the direct effects and a putative neuroprotective role of A₁R upregulation in neurons, we have generated and functionally tested a tetracycline-regulated expression system for mouse A₁R. The results presented here provide direct evidence that the upregulation of A₁R enhances neuronal survival against NMDA-induced excitotoxicity.

Materials and Methods

Materials

Dulbecco's modified Eagle's medium (DMEM), Neuronal Base medium (NB), Hanks' balanced salt solution, phosphate-buffered saline (PBS), sodium pyruvate, L-glutamine, penicillin–streptomycin, HEPES, NeuroMix, fetal bovine serum and trypsin–EDTA were from PAA laboratories (Cölbe, Germany). Lipofectamine 2000, Opti-MEM and Alexa Fluor 647 donkey anti-rabbit IgG were from Invitrogen (Karlsruhe, Germany). CPA and DPCPX were from Tocris Bioscience (Bristol, UK). Adenosine deaminase (ADA) was from Roche Biochemicals (Mannheim, Germany). Anti-adenosine A₁ receptor rabbit polyclonal antibody was from Abcam (Cambridge, UK). Anti-actin rabbit polyclonal antibody and all other chemicals were from Sigma-Aldrich (Munich, Germany).

Plasmid and DNA Construct Cloning

We have previously isolated and subcloned the mouse adenosine A₁ receptor cDNA into pCRII cloning vector [16]. A NotI/HindIII fragment, containing the full-length adenosine A₁ receptor coding region, was excised from a pCRII vector and ligated into a NotI/HindIII digested pTRE-tight-BI-AcGFP-BGH tet-inducible bidirectional expression vector. Alternatively, a red fluorescent protein-expressing construct (pTRE-tight-BI-mCherry-A₁R-BGH) was created by XbaI/EcoRI substitution of the AcGFP with mCherry (Fig. 1). pTRE-tight-BI-AcGFP-BGH plasmid containing EcoRV subcloned human beta-globin intron and pTet-Off transactivator-expressing plasmid were a kind gift from K.-P. Knobloch (Department of Neuropathology, University Freiburg).




Fig. 1 Tetracycline-regulated (Tet-Off) expression of the mouse A₁R. The full-length mouse adenosine A₁ receptor coding region (*mA₁R cDNA*) was ligated into NotI/HindIII digested pTRE-tight-BI-AcGFP-BGH tetracycline-inducible bidirectional expression vector, containing EcoRV subcloned human beta-globin intron (*BGH intron*). Alternatively, red fluorescent protein expressing construct (pTRE-tight-BI-mCherry-A₁R-BGH) was created by XbaI/EcoRI substitution of AcGFP with mCherry. The human cytomegalovirus (CMV) promoter controls the expression of the *tTA* gene product, which induces the simultaneous transcription of the A₁R and AcGFP/mCherry, by binding to a tetracycline-responsive element (*TRE*) containing a bidirectional promoter (*P_{miniCMV}*). Thus, the gene expression could be blocked by tetracycline or its stable analogue doxycycline (*Dox*). *SV40pA* simian-virus 40 polyadenylation signal

Cell Culture and Transfection

The human embryonic kidney 293 (HEK293) cells were maintained in DMEM 1 g/l glucose, 10 % fetal calf serum, penicillin 100 U/ml and streptomycin 100 µg/ml at 5 % CO₂ and 37 °C and were subcultured twice a week in order to prevent from reaching confluence. The HEK293 cells were transfected with Lipofectamine 2000 according to the manufacturer's instructions. Primary neuronal cultures from mouse embryo (~E16.5) were established as described previously [14]. The cells were grown on poly-L-lysine-coated glass cover slips in 24-well plates. After 4 days in vitro, the cultures were transfected using the Ca²⁺-phosphate transfection method described by Jiang et al. [17], except that the cells were maintained only in NB medium supplemented with NeuroMix, 1 mM sodium pyruvate, 0.5 mM L-glutamine, penicillin 100 U/ml and streptomycin 100 µg/ml. The neuronal purity, determined by neuronal nuclei (NeuN) staining, was 90–95 % (data not shown). The HEK293 cells were transfected with pcDNA-A₁R or co-transfected with pTRE-tight-BI-AcGFP/mCherry-A₁R-BGH and pTet-Off transactivator-expressing plasmid in a 1:5 ratio and treated with 100 ng/ml doxycycline for 48 h before the experiments. The primary neuronal cultures were co-transfected with pTRE-tight-BI-AcGFP/mCherry-A₁R-BGH or pTRE-tight-BI-AcGFP/mCherry and pTet-Off transactivator-expressing plasmid in a 1:2 ratio and used for experiments after 48 h in vitro.

Western Blot Analysis

The cells were washed twice with ice-cold PBS and then lysed with Laemmli sample buffer (50 mM Tris–HCl (pH

6.8), 2 % SDS, 5 % 2-mercaptoethanol, 0.2 M DTT, 10 % glycerin, 0.04 % Pyronin Y) and boiled at 95 °C. The extracts were separated on 10 % SDS-PAGE and electrotransferred to polyvinylidene fluoride membranes. The membranes were blocked with 5 % nonfat dry milk in PBS-T (1 % Tween 20 in PBS) for 1 h at room temperature (RT) and then incubated with the respective primary antibody (rabbit polyclonal anti-adenosine A₁ receptor 1:1,000 and rabbit polyclonal anti-actin 1:5,000) overnight at 4 °C. The membranes were washed three times for 5 min in PBS-T and incubated for 1 h at RT with secondary horseradish peroxidase-conjugated antibody, diluted in PBS-T and then washed again three times for 5 min in PBS-T. The signal was detected using an enhanced chemiluminescent detection reagent kit (GE Healthcare; München, Germany) and a Fusion-SL imaging system (peQlab; Erlangen, Germany). The immunoreactive bands along with their respective loading controls were quantified densitometrically by using the TINA 2.09 software (ISBM; Oxford, UK).

Whole-Cell Patch Clamp Recordings

The cells were transferred to the submerged-type recording chamber and continuously perfused with extracellular recording solution containing 135 mM NaCl, 2 mM TEA, 2 mM MgCl₂, 10 mM HEPES and 20 mM BaCl₂ (pH 7.35) at a flow rate of 5–10 ml/min (chamber volume approximately 2 ml); 10 µl of stock solutions of CPA (10 µM) and DPCPX (1 µM) was directly applied to the recording chamber that had a volume of 1 ml. The recordings were performed on cells identified by using infrared differential interference contrast video microscopy (Axioskop 2 FS plus, Zeiss Germany, IMAGO-VGA, Till Photonics, Germany), and the transfected GFP cells were visualised at 475-nm wavelength. The recording pipettes were pulled from borosilicate glass tubing (2.0-mm outer diameter, 0.5-mm wall thickness; Hilgenberg, Germany). The patch pipettes with resistances 4–7 MΩ were filled with a solution containing 140 mM CsCl, 2 mM MgCl₂, 2 mM Na₂ATP, 0.3 mM NaGTP, 10 mM EGTA and 10 mM HEPES (pH 7.35). Patch clamp recordings were performed with an EPC-9 amplifier (HEKA, Lambrecht, Germany), and the signals were filtered at 5 and 10 kHz and stored online. For data acquisition and analysis, Pulse and PulseFit softwares (HEKA, Lambrecht, Germany) were used. Data represent the mean values ± SEM of the averages of 10–15 consecutive sweeps of current amplitudes of five to seven cells per condition.

Induction of Excitotoxicity

Neurons maintained in doxycycline-free medium were used after 7 days in culture. Cells were incubated for 1 h with 1 U/ml ADA and then either stimulated for 1 h with NMDA at

various concentrations or incubated for 15 min with 100 nM CPA or 100 nM DPCPX before they were subjected to NMDA challenge for 1 h. Following the NMDA treatment, the media were refreshed and the neuronal cultures were incubated with propidium iodide (PI, 1:1,000) for 18 h before immunocytochemistry.

Immunocytochemistry

Immunocytochemistry was performed at RT unless mentioned otherwise. Cultures were washed twice for 5 min in PBS and then fixed with 4 % paraformaldehyde in PBS for 20 min. Subsequently, the cultures were washed twice with PBT (PBS/A (1 % bovine serum albumin in PBS) and 0.1 % Tritone X-100) and further incubated with PBT containing 5 % goat serum for 1 h. Cultures were incubated with the primary antibody (rabbit polyclonal anti-adenosine A₁ receptor—1:1,000) diluted in PBS/A overnight at 4 °C. After three washes with PBS/A, the cells were incubated with specific dye-conjugated secondary antibody (Alexa Fluor 647 donkey anti-rabbit—1:1,000) diluted in PBS/A for 1 h. Cultures were washed twice with PBS before incubation with 4'-6-diamidino-2-phenylindole (DAPI, 1:1,000) in PBS to label cell nuclei for 10 min. After a final washing in PBS, the cover slips were mounted on slides using Mowiol-DABCO. All immunofluorescence images were detected and photographed using LSM-U-2 laser scanning confocal microscope and documented using ZEN 2009 software (Carl Zeiss, Germany).

Counting and Statistical Analysis

The number of PI- and GFP-positive cells was determined by counting the number of cells in three randomly chosen microscopic observation fields per cover slip. Data represent the mean ± SEM of experiments performed at least three times on independent culture preparations, each performed in triplicate. Statistical analysis of the data was performed using one-way ANOVA, and statistical significance between the two groups was determined by applying Student's *t* test. Analysis of the electrophysiology and Western blot data was carried out using Student's *t* test performed on SPSS 17.0 software (SPSS Inc., Chicago, USA). In all cases, values of *p* < 0.05 were considered statistically significant.

Results

Generation of the Tetracycline-Regulated A₁R Expression System

In order to create a conditionally regulated gene expression system with simultaneous expression of A₁R and a fluorescent

protein reporter gene, we cloned the full-length mouse adenosine A₁ receptor coding region (mA₁R cDNA) into a pTRE-tight-BI-AcGFP-BGH (pTRE-GFP) tetracycline-inducible bidirectional expression vector, containing an EcoRV subcloned human beta-globin intron (BGH intron). Alternatively, a red fluorescent protein reporter gene-expressing construct (pTRE-tight-BI-mCherry-A₁R-BGH) was created by substitution of AcGFP with mCherry. The system requires co-transfection of two different plasmids: pTet-Off, encoding the tetracycline transactivator (tTA) gene product, which induces the transcription of A₁R and AcGFP/mCherry by binding to a tetracycline-responsive element (TRE) containing a bidirectional promoter (P_{miniCMV}) located on the second plasmid—pTRE-tight-BI-AcGFP/mCherry-A₁R-BGH (pTRE-GFP/mCherry-A₁R). The gene expression can be blocked by tetracycline or its stable analogue doxycycline, which inhibits the tTA binding to the TRE promoter (Fig. 1). In order to enhance the expression of the A₁R, we inserted the human beta-globin intron sequence (BGH intron) after the A₁R coding region [18].

Tetracycline-Regulated Expression of Mouse A₁R in HEK293 Cells

The tetracycline-regulated A₁R expression system was first tested in cultured cortical neurons by Western blotting or immunohistochemistry. However, a significant effect of doxycycline treatment on A₁R expression was not found. This most likely reason was the low transfection efficiency of primary neurons, which was less than 10 % (see below) and the fact that neurons already endogenously express A₁R. We assumed that an increase caused by our construct was not pronounced enough to be reliably detected. We therefore used HEK293 cells for further characterization of our system, since these cells are easily transfected and do not express endogenous A₁R (see for review [19]). Initially, we compared the A₁R protein expression of pTRE-GFP/mCherry-A₁R and pTet-Off co-transfected (pTRE-A₁R) HEK293 cells in the absence of doxycycline with those transfected with the pcDNA3-A₁R expression plasmid, where high levels of constitutive A₁R expression, directed by the CMV promoter, are achieved. The tetracycline-regulated A₁R expression system showed a slightly less expression compared to the widely used pcDNA3 vector. Addition of 100 ng/ml doxycycline strongly inhibited the A₁R protein expression down to basal endogenous levels in HEK293 cells (Fig. 2a).

The doxycycline-regulated A₁R expression in HEK293 cells was further analysed by immunocytochemistry. We did not observe a specific A₁R staining in the non-transfected HEK293 cells. However, in the pTRE-A₁R cultures, we found a high number of A₁R-positive cells, similar to that observed in pcDNA3-A₁R-transfected HEK293 cells (Fig. 2b). Though only 40–60 % of the A₁R stained cells


were dual positive for GFP and A₁R (Fig. 2c), we did not find any cell positive only for GFP. Addition of 100 ng/ml doxycycline strongly inhibited both A₁R and GFP expression to undetectable levels (Fig. 2b).

A₁R-Mediated Inhibition of Voltage-Gated Ca²⁺ Channels in A₁R-Transfected HEK293 Cells

It has been previously reported that the A₁R inhibits Ca²⁺ influx by modulation of voltage-gated Ca²⁺ channels [20, 21]. Accordingly, to test the functionality of expressed A₁R, we performed whole-cell patch clamp recordings. First, the effect of the selective A₁R agonist CPA on voltage-gated Ca²⁺ channels of pTet-Off and pTRE-GFP (mock transfected) or pTRE-GFP-A₁R (A₁R transfected) co-transfected primary neurons was tested. The GFP reporter gene expression allowed us to select the transfected cells, and indeed an increased inhibitory effect of CPA on Ca²⁺ currents was detected occasionally (Suppl. Fig. 3). However, patching transfected neurons was extremely difficult and most of the time a stable recording was not possible in transfected cells. This most likely was caused by the transfection procedure, because non-transfected neurons were patched with no such problems (data not shown). Therefore, it was decided to continue this approach in HEK293 cells that often are used for electrophysiological experiments (see for review [19]) and are known to express endogenous voltage-dependent Ca²⁺ channels that slightly differ in their pharmacological properties from classical N- and L-type channels but are functionally regulated by G_{i/o} proteins [22, 23].

Accordingly, we tested the effect of the selective A₁R agonist CPA on endogenous voltage-gated Ca²⁺ channels of pTet-Off and pTRE-GFP (mock transfected) or pTRE-GFP-A₁R (A₁R transfected) co-transfected HEK293T cells. The holding potential was −70 mV, and the whole-cell Ba²⁺ currents through Ca²⁺ channels were measured by 50-ms steps to a recording potential of +10 mV. The currents reached typical peak amplitudes of −50 to −400 pA at 0 mV (Fig. 3a, Suppl. Fig. 2) and were completely blocked by 25 μM CdCl (n=2, data not shown). We found that 10 μM CPA strongly inhibited voltage-dependent Ba²⁺ currents in A₁R-transfected cells, while it did not significantly affect current amplitudes of mock-transfected cells (Fig. 3a, b). The effect of 10 μM CPA was completely antagonised in the presence of the adenosine A₁R antagonist DPCPX (1 μM), suggesting that the observed current inhibition in A₁R-transfected cells was specifically mediated by the expressed A₁R (Fig. 3c); 1 μM DPCPX alone had no significant effect both in A₁R-transfected cells (Fig. 3c) and in mock-transfected cultures (data not shown). Neither CPA nor DPCPX significantly changed the kinetics of the recorded currents (data not shown).

Fig. 2 Tetracycline-regulated expression of mouse A₁R in HEK293 cells. **a** Representative Western blot and densitometric quantification of A₁R protein levels in control non-transfected (NT), *pcDNA3-A₁R* expression plasmid transfected and pTRE-tight-BI-AcGFP/mCherry-A₁R-BGH and pTet-Off transactivator-expressing plasmid co-transfected (*pTRE-A₁R*) HEK293T cells in the absence (–) or presence (+) of 100 ng/ml doxycycline. The mouse whole brain lysate was used as a positive control for A₁R. Data represent a densitometric quantification of relative mean levels of A₁R protein normalised to actin ($n=3$, $**p<0.01$ in comparison to NT, Student's *t* test). **b** Representative fluorescence photomicrographs for three independent experiments depicting the A₁R (red), GFP (green) and nuclei counterstained with DAPI (blue) in transfected HEK293T cells; 100 ng/ml doxycycline treatment strongly inhibits A₁R/GFP expression (*pTRE-GFP-A₁R*+Dox). **c** A₁R staining and GFP fluorescence co-localises in pTRE-A₁R-transfected HEK293T cells



Upregulated A₁R Expression Enhances the Survival of Transfected Primary Cortical Neurons

The neuronal A₁R has a key neuroprotective function, and it has long been suggested that upregulation of A₁R expression increases its neuroprotective capacities (see for review [5, 13]). In order to investigate the role of A₁R overexpression on neuronal survival, primary neuronal cultures were co-transfected with pTet-Off transactivator-expressing plasmid and pTRE-GFP/mCherry-A₁R (A₁R transfected) or pTRE-GFP/mCherry (mock transfected) plasmids in a ratio of 2:1 by the Ca²⁺-phosphate transfection method described by Jiang et al. [17]. Using this transfection protocol, we were able to achieve up to 10 % transfection efficacy while maintaining more than 60 % survival of the transfected neurons (Fig. 4b), determined by counting of GFP/mCherry-positive cells and PI staining of the dead cell nuclei (Suppl. Fig. 1), respectively.

We found that in control conditions, the A₁R-transfected neurons had a significantly higher survival than mock-transfected neurons, expressing only the reporter gene

GFP/mCherry (Fig. 4b). In all experiments, non-neuronal cells, negative for neuronal nuclei marker NeuN, were excluded from the analysis.

It is well known that treatment with high concentration of glutamate for 1 h causes cell death in cultured embryonic cortical neurons that can be abolished by NMDA receptor antagonists [14]. Thus, 48 h after the transfection, we stimulated mock-transfected and A₁R-transfected neuronal cultures, simultaneously with non-transfected neurons, with various concentrations of NMDA for 1 h. Neuronal survival was assessed 18 h later. Treatment with 10, 50 and 100 μ M NMDA caused a concentration-dependant increase of PI-positive cells in non-transfected and mock-transfected neuronal cultures (Fig. 4a, b). In contrast, stimulation with 10 μ M NMDA was not able to significantly increase the number of PI-labelled A₁R-transfected neurons, compared to control, non-NMDA-treated A₁R-transfected cultures. In addition, we found significantly reduced number of PI-stained GFP/mCherry-positive neurons in all NMDA-treated A₁R-transfected cultures, compared to the corresponding mock-transfected neurons (Fig. 4b). Interestingly, the efficacy (slope


Fig. 3 A₁R-mediated inhibition of voltage-gated Ca²⁺ channels in transfected HEK293 cells expressing upregulated A₁R. The holding potential of cells was −70 mV and whole-cell Ba²⁺ currents were measured by 50-ms steps to a recording potential of +10 mV; 10 μl of stock solutions of CPA (10 μM) and DPCPX (1 μM) was directly applied to the recording chamber that had a volume of 1 ml. **a** Representative whole-cell voltage-gated Ba²⁺ currents of the pTet-Off and pTRE-tight-BI-AcGFP (mock transfected) or pTRE-tight-BI-AcGFP-A₁R-BGH (A₁R transfected) co-transfected HEK293T cells, baseline in black and 10 μM CPA effect in grey. **b** Current inhibition by 10 μM CPA in mock (*n*=7) and A₁R (*n*=5) transfected HEK293T cells (averaged peak current amplitude in percent ± SEM of baseline currents; **p*<0.01, Student's *t* test). **c** Comparison of the effects of 10 μM CPA, 1 μM DPCPX or both together on A₁R-transfected HEK293T cells. Data represent the amplitude of the voltage-gated Ba²⁺ currents normalised to baseline (±SEM of the averaged peak amplitudes of 10–15 consecutive sweeps; *n*=5–7 cells per condition; **p*<0.01 in comparison to baseline, Student's *t* test)

of concentration dependency) of NMDA to induce neuronal death was not changed between non-transfected and mock-transfected cells. In neurons, where A₁R was upregulated, the neurotoxic effect of NMDA was significantly impaired (Fig. 4c). We did not observe any significant differences in cell viability between mCherry and GFP-transfected neurons (data not shown).

Modulation of A₁R Upregulation-Mediated Neuroprotection by Pretreatment with ADA, CPA and DPCPX

We show here that upregulation of A₁R expression enhances the survival of transfected primary neurons without specific A₁R agonist stimulation, suggesting for the presence of adenosine in the culture media. In order to test that hypothesis, the extracellular adenosine was removed by pre-incubating the transfected neuronal cultures with 1 U/ml ADA for 1 h, which is sufficient to degrade the adenosine present in the media. Thereafter, neurons were challenged with 50 μM NMDA for 1 h and cell viability was assessed. Our results show that ADA treatment had no significant effect on the survival of the mock-transfected neuronal cultures; however, it completely abolished the neuroprotective effect of upregulated A₁R expression in both the control and 50 μM NMDA-treated A₁R-transfected neurons (Fig. 5a).

To further confirm the involvement of A₁R in the observed neuroprotective effect, we pre-incubated cultures with the selective A₁R agonist CPA for 15 min prior to the NMDA stimulation. Pretreatment with 100 nM CPA of mock-transfected neurons had no significant effect on neuronal survival at NMDA concentration of 10 and 50 μM. We detected a slight neuroprotective effect of CPA in 100 μM NMDA-challenged mock-transfected neurons (Fig. 5b). In contrast, treatment with CPA strongly enhanced survival in A₁R-transfected neurons; 100 nM CPA treatment completely abolished neurotoxicity of 10 and 50 μM



NMDA and strongly reduced the cell death even in response to 100 μM NMDA in A₁R-transfected neurons (Fig. 5b).


In order to further investigate the specificity of the A₁R upregulation-mediated enhancement of the survival of

Fig. 4 Effect of upregulated A₁R expression on the survival of primary cortical neurons after NMDA-induced excitotoxicity. Primary neuronal cultures were directly challenged with NMDA (10, 50 and 100 μ M) for 1 h (non-transfected) (a) or after co-transfection with pTRE-GFP/mCherry-A₁R (A₁R transfected) or pTRE-GFP/mCherry (mock transfected) and pTet-Off plasmid in a 1:2 ratio (b). Neuronal survival was assessed 18 h following the NMDA treatment by immunocytochemistry using PI staining of the dead cell nuclei. Percentage of PI-stained nuclei vs. the total number of DAPI-stained nuclei for the non-transfected (a) or the PI-stained nuclei of the GFP/mCherry-expressing cells vs. the total number of GFP-positive cells for transfected cultures (b) (\pm SEM; $n=5$; * $p<0.05$, ** $p<0.01$, # $p<0.05$, ## $p<0.01$ in comparison to the respective control, Student's t test). c The slope comparison of the linear regression lines representing the NMDA- (10, 50 and 100 μ M) induced concentration-dependent cell death in non-transfected, GFP(mCherry)-expressing (mock transfected) and A₁R/GFP(mCherry)-expressing (A₁R transfected) neuronal cultures. Data represent the mean \pm SEM of five independent experiments

transfected primary cortical neurons, the specific A₁R antagonist DPCPX was used. Blockade of A₁R by pre-incubation with 100 nM DPCPX completely abolished the neuroprotective effect of A₁R upregulation in both control and 50 μ M NMDA-treated A₁R-transfected neurons, but it did not affect the neuronal survival of mock-transfected cultures (Fig. 5c). Similarly, pre-incubation with 100 nM DPCPX for 15 min followed by 15 min 100 nM CPA stimulation abolished both the effects of A₁R upregulation and CPA treatment on neuronal survival in A₁R-transfected cultures and it did not affect the number of the PI-positive GFP/mCherry-expressing mock-transfected neurons (Fig. 5d).

Discussion


Extracellular adenosine acting on neuronal A₁R functions as a major endogenous neuroprotective system in the brain (see for review [5, 12, 13, 24]). Although the precise mechanism by which neuroprotection is achieved is not yet clear (see for review [9]), it seems that A₁R, to a large extent, controls the threshold of onset of neuronal damage. Accordingly, it has long been suggested that the neuroprotective effects of A₁R are increased following receptor upregulation; thus, the enhancement of neuronal A₁R expression attenuates neuronal damage in pathological conditions (see for review [5, 13]). Indeed, we recently reported that the cytokines IL-6 and oncostatin M upregulate neuronal A₁R expression and thereby boost neuroprotection in vitro and in vivo [14, 15]. Interestingly, an upregulation of A₁R expression has been observed in mice and rats after chemically induced seizures and in post-mortem tissue of humans suffering from epilepsy [25–27]. This seizure-induced upregulation of A₁R was not observed in IL-6 deficient animals, which was correlated with higher seizure scores and increased mortality, again suggesting that an increased A₁R expression is neuroprotective [14]. An



increase of neuronal A₁R expression has yet only been achieved by chronic antagonist treatment [28–31] or stimulation with cytokines [14, 15]. Since these pharmacological interventions may also have effects other than the upregulation of A₁R expression, we here aimed to analyse the direct effects of A₁R upregulation.

In order to investigate the direct effects of upregulation of A₁R expression in neurons, we have generated a tetracycline-

Fig. 5 Effect of ADA, CPA and DPCPX treatment on the A₁R upregulation-mediated enhanced survival of transfected primary cortical neurons and after NMDA-induced excitotoxicity. The primary neuronal cultures were co-transfected with pTRE-GFP/mCherry-A₁R (A₁R transfected) or pTRE-GFP/mCherry (mock transfected) and pTet-Off transactivator-expressing plasmid in a 1:2 ratio. After 48 h in vitro, the neurons were pre-incubated with 1 U/ml ADA for 1 h (a), 100 nM CPA for 15 min (b), 100 nM DPCPX for 15 min (c) or 100 nM DPCPX for 15 min, followed by 100 nM CPA for 15 min (d), and were subsequently challenged with NMDA (10, 50 and 100 μ M) for 1 h. Neuronal survival was assessed 18 h following the NMDA treatment by immunocytochemistry using PI staining of the dead cell nuclei. Percentage of the PI-stained nuclei of the GFP/mCherry-expressing cells vs. the total number of GFP/mCherry-positive cells (\pm SEM; $n=3$; * $p<0.05$, ** $p<0.01$, Student's t test)



regulated expression system with a bidirectional promoter, directing the simultaneous expression of mouse A₁R and

GFP/mCherry reporter genes. The system was initially tested in transiently transfected HEK293 cells, which were chosen

due to their high transfection efficacy and low expression of endogenous A₁R. We have previously cloned the mouse A₁R [16]. In the present study, we subcloned the mouse A₁R cDNA into the Clontech pTRE-tight-BI-AcGFP/mCherry tetracycline-inducible bidirectional expression vector. Thus, the expression of the reporter gene AcGFP/mCherry, which encodes the green/red fluorescent protein, simultaneously with A₁R is a suitable control for the transfection and expression efficacy and its TRE promoter allows conditional regulation. It is shown here that this system allowed both A₁R and reporter gene expression to be tightly regulated by the tetracycline analogue doxycycline. The fact that only 50 % of A₁R-positive cells also showed a fluorescent signal for GFP or mCherry (data not shown) is most likely due to the fact that the fluorescent signals are quenched by fixation. Compared to the widely used pcDNA3 vector with its CMV promoter that drives A₁R expression about threefold higher in HEK293 cells, our tetracycline-regulated expression system reached lower levels of about twofold upregulation of A₁R expression, which was more comparable to what has been achieved by pharmacological means in cultured neurons or in vivo [14].

The mouse A₁R, encoded by the cDNA used in the present study, has been characterized previously using functional studies and radioligand binding assays [16]. Since several lines of evidence indicate that the A₁R inhibits multiple voltage-gated Ca²⁺ channel subtypes in neurons [20, 21, 32, 33], we performed whole-cell patch clamp recordings to assess the function of the transfected A₁R construct. HEK293 cells express endogenous voltage-dependent Ca²⁺ channels which differ in their pharmacological properties from classical N- and L-type channels and are functionally regulated by G_{i/o} proteins [22, 23]. We demonstrated that upon selective agonist activation, the expressed A₁R inhibits endogenous voltage-gated Ca²⁺ channels specifically in A₁R-transfected HEK293 cells showing that the expressed A₁R is functional and corroborating earlier findings [16].

To investigate the role of A₁R upregulation in neuronal survival, we transfected primary cortical cultures with our system, maintained them in the absence of doxycycline and challenge them with various concentration of NMDA. We show here that primary neurons with upregulated A₁R expression display significantly enhanced survival against NMDA-induced excitotoxicity. Further pharmacological studies, using the selective A₁R agonist CPA and antagonist DPCPX, confirmed that the observed enhanced neuroprotection is specifically mediated by the upregulated expression of the A₁R.

The Ca²⁺-phosphate transfection method [17], which we used in primary neurons, is a stressful event that caused significant neuronal loss compared to non-transfected cultures. Thus, mock-transfected neurons exhibited more cell death than non-transfected cultures. However, the sensitivity

of the neurons against NMDA was unchanged, since the concentration-dependent increase in NMDA-dependent neuronal death had the same slope in non-transfected neurons as compared to mock-transfected cells. In contrast to the mock-transfected neurons, those with upregulated A₁R expression did not differ in neuronal death from non-transfected cells. Furthermore, the impact of NMDA challenge in these neurons was less severe since the concentration-dependent increase of NMDA-induced neuronal death was less steep than in neurons without upregulated A₁R expression. Thus, the presented results clearly show that an increased A₁R expression is protective for neurons, not only under excitotoxic conditions but also in other neuronal stressors, like the transfection and culture procedures.

It is long known that energy imbalance causes a rapid release of adenosine in brain tissue (see for review [9]). The protective function of A₁R upregulation is completely abolished in the presence of ADA or DPCPX, suggesting that also cultured cortical neurons release sufficient amounts of adenosine to stimulate protective A₁R. Since there was no effect of either ADA or DPCPX treatment in mock-transfected cells, it is indicated that the receptor expression level in mock-transfected neurons is not high enough for the released adenosine to be neuroprotective. These results are therefore in agreement with the long standing notion that the agonistic potency of adenosine strongly depends on the density of receptors in the cellular membrane (see for review [9, 12]). Thus, two basal properties of adenosine (release by cellular stress and receptor density-dependent effects) are also reflected in our cell culture system. However, the released adenosine most likely did not reach high enough concentrations to fully activate the A₁R response, an assumption based on the observation that an additional treatment with the A₁R-specific agonist CPA strongly enhanced neuroprotection in neurons with upregulated A₁R expression. It should be noted here that even at very high concentrations of NMDA, the stimulation with 100 nM CPA almost completely blocked excitotoxicity when A₁R is upregulated, confirming the powerful protection that can be achieved by A₁R upregulation.

In summary, we have generated and functionally tested a tetracycline-regulated expression system, which allows the simultaneous expression of the mouse A₁R and GFP/mCherry reporter genes. The presented data provide for the first time direct evidence that the upregulation of A₁R expression enhances the neuronal survival. The conditionally regulated A₁R expression system is a useful tool for the generation of transgenic animals, where the role of A₁R upregulation can be further investigated in vivo.

Acknowledgments The study was funded by grants from the German Research Council (DFG) (CA 115/5-4) to D.v.C. and K.B. and from the EU FP7 program “MoodInflame” to D.v.C.

References

- Faden AI, Demediuk P, Panter SS, Vink R (1989) The role of excitatory amino acids and NMDA receptors in traumatic brain injury. *Science* 244(4906):798–800
- Dirnagl U, Iadecola C, Moskowitz MA (1999) Pathobiology of ischaemic stroke: an integrated view. *Trends Neurosci* 22(9):391–397
- Vincent P, Mulle C (2009) Kainate receptors in epilepsy and excitotoxicity. *Neuroscience* 158(1):309–323
- Dong XX, Wang Y, Qin ZH (2009) Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. *Acta Pharmacol Sin* 30(4):379–387
- Dunwiddie TV, Masino SA (2001) The role and regulation of adenosine in the central nervous system. *Annu Rev Neurosci* 24:31–55
- Barrie AP, Nicholls DG (1993) Adenosine A1 receptor inhibition of glutamate exocytosis and protein kinase C-mediated decoupling. *J Neurochem* 60(3):1081–1086
- Trussell LO, Jackson MB (1985) Adenosine-activated potassium conductance in cultured striatal neurons. *Proc Natl Acad Sci U S A* 82(14):4857–4861
- de Mendonca A, Sebastiao AM, Ribeiro JA (1995) Inhibition of NMDA receptor-mediated currents in isolated rat hippocampal neurones by adenosine A1 receptor activation. *Neuroreport* 6(8):1097–1100
- Gomes CV, Kaster MP, Tome AR, Agostinho PM, Cunha RA (2011) Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. *Biochim Biophys Acta* 1808(5):1380–1399
- Dalpiaz A, Manfredini S (2002) Adenosine A(1) receptor: analysis of the potential therapeutic effects obtained by its activation in the central nervous system. *Curr Med Chem* 9(21):1923–1937
- Stone TW (2002) Purines and neuroprotection. *Adv Exp Med Biol* 513:249–280
- Fredholm BB (2007) Adenosine, an endogenous distress signal, modulates tissue damage and repair. *Cell Death Differ* 14(7):1315–1323
- Schubert P, Ogata T, Marchini C, Ferroni S, Rudolph K (1997) Protective mechanisms of adenosine in neurons and glial cells. *Ann N Y Acad Sci* 825:1–10
- Biber K, Pinto-Duarte A, Wittendorp MC, Dolga AM, Fernandes CC, Von Frijtag Drabbe Kunzel J, Keijser JN, de Vries R, Ijzerman AP, Ribeiro JA, Eisel U, Sebastiao AM, Boddeke HW (2008) Interleukin-6 upregulates neuronal adenosine A1 receptors: implications for neuromodulation and neuroprotection. *Neuropsychopharmacology* 33(9):2237–2250
- Moidunny S, Dias RB, Wesseling E, Sekino Y, Boddeke HW, Sebastiao AM, Biber K (2010) Interleukin-6-type cytokines in neuroprotection and neuromodulation: oncostatin M, but not leukemia inhibitory factor, requires neuronal adenosine A1 receptor function. *J Neurochem* 114(6):1667–1677
- Wittendorp MC, von Frijtag Drabbe Kunzel J, Ijzerman AP, Boddeke HW, Biber K (2004) The mouse brain adenosine A1 receptor: functional expression and pharmacology. *Eur J Pharmacol* 487(1–3):73–79
- Jiang M, Deng L, Chen G (2004) High Ca(2+)-phosphate transfection efficiency enables single neuron gene analysis. *Gene Ther* 11(17):1303–1311
- Nott A, Meislin SH, Moore MJ (2003) A quantitative analysis of intron effects on mammalian gene expression. *RNA* 9(5):607–617
- Thomas P, Smart TG (2005) HEK293 cell line: a vehicle for the expression of recombinant proteins. *J Pharmacol Toxicol Methods* 51(3):187–200
- Mynlieff M, Beam KG (1994) Adenosine acting at an A1 receptor decreases N-type calcium current in mouse motoneurons. *J Neurosci* 14(6):3628–3634
- Zhu Y, Ikeda SR (1993) Adenosine modulates voltage-gated Ca²⁺ channels in adult rat sympathetic neurons. *J Neurophysiol* 70(2):610–620
- Berjukow S, Doring F, Froschmayr M, Grabner M, Glossmann H, Hering S (1996) Endogenous calcium channels in human embryonic kidney (HEK293) cells. *Br J Pharmacol* 118(3):748–754
- Vasquez C, Navarro-Polanco RA, Huerta M, Trujillo X, Andrade F, Trujillo-Hernandez B, Hernandez L (2003) Effects of cannabinoids on endogenous K⁺ and Ca²⁺ currents in HEK293 cells. *Can J Physiol Pharmacol* 81(5):436–442
- Cunha RA (2005) Neuroprotection by adenosine in the brain: from A(1) receptor activation to A (2A) receptor blockade. *Purinergic Signal* 1(2):111–134
- Pagonopoulou O, Angelatou F, Kostopoulos G (1993) Effect of pentylenetetrazol-induced seizures on A1 adenosine receptor regional density in the mouse brain: a quantitative autoradiographic study. *Neuroscience* 56(3):711–716
- Vanore G, Giraldez L, de Lores R, Arnaiz G, Girardi E (2001) Seizure activity produces differential changes in adenosine A1 receptors within rat hippocampus. *Neurochem Res* 26(3):225–230
- Angelatou F, Pagonopoulou O, Maraziotis T, Olivier A, Villemure JG, Avoli M, Kostopoulos G (1993) Upregulation of A1 adenosine receptors in human temporal lobe epilepsy: a quantitative autoradiographic study. *Neurosci Lett* 163(1):11–14
- Fredholm BB (1982) Adenosine actions and adenosine receptors after 1 week treatment with caffeine. *Acta Physiol Scand* 115(2):283–286
- Lupica CR, Berman RF, Jarvis MF (1991) Chronic theophylline treatment increases adenosine A1, but not A2, receptor binding in the rat brain: an autoradiographic study. *Synapse* 9(2):95–102
- Lupica CR, Jarvis MF, Berman RF (1991) Chronic theophylline treatment in vivo increases high affinity adenosine A1 receptor binding and sensitivity to exogenous adenosine in the in vitro hippocampal slice. *Brain Res* 542(1):55–62
- Tsutsui S, Schnermann J, Noorbakhsh F, Henry S, Yong VW, Winston BW, Warren K, Power C (2004) A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. *J Neurosci* 24(6):1521–1529
- Scholz KP, Miller RJ (1991) Analysis of adenosine actions on Ca²⁺ currents and synaptic transmission in cultured rat hippocampal pyramidal neurones. *J Physiol* 435:373–393
- McCool BA, Farroni JS (2001) A1 adenosine receptors inhibit multiple voltage-gated Ca²⁺ channel subtypes in acutely isolated rat basolateral amygdala neurons. *Br J Pharmacol* 132(4):879–888